Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015;15(11):1315-26.
doi: 10.1586/14737140.2015.1090879. Epub 2015 Nov 2.

Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer

Jordan Lerner-Ellis, Sam Khalouei  1 , Victoria Sopik  2 , Steven A Narod  2
Affiliations
Review

Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer

Jordan Lerner-Ellis et al. Expert Rev Anticancer Ther. 2015.

Abstract

Multigene panel tests are being increasingly used for the genetic assessment of women with an apparent predisposition to breast cancer. Here, we review all studies reporting results from individuals who have undergone multigene panel testing for hereditary breast cancer. Across all gene panel studies, the prevalence of pathogenic mutations was highest in BRCA1 (5.3%) and BRCA2 (3.6%) and was lowest in PTEN (0.1%), CDH1 (0.1%) and STK11 (0.01%). After BRCA1/2, the prevalence of pathogenic mutations was highest in CHEK2 (1.3%), PALB2 (0.9%) and ATM (0.8%). The prevalence of variants of unknown significance was highest in ATM (9.6%). Based on the prevalence and penetrance of pathogenic mutations and the prevalence of variants of unknown significance, it is our interpretation that BRCA1, BRCA2, PALB2 and CHEK2 are the best candidates for inclusion in a clinical multigene breast cancer panel.

Keywords: breast cancer; gene panel; genetic testing; next-generation sequencing; precision medicine.

PubMed Disclaimer

LinkOut - more resources